Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 2, 2013, Pages 261-270

  Hatoum, Hind T ^a   Crawford, E David ^b   Nielsen, Sandy Kildegaard ^c   Lin, Swu Jane ^d   Marshall, Dennis C ^e  

^a Hind T Hatoum and Company   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Ferring Pharmaceuticals AS   (Denmark)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Ferring Pharmaceuticals Inc USA   (United States)

Author keywords

ADT; cost effectiveness; degarelix; Markov simulation models; prostate cancer; QALY

Indexed keywords

BICALUTAMIDE; DEGARELIX; DOCETAXEL; LEUPRORELIN; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; HUMAN; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SHORT FORM 12;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; COST-BENEFIT ANALYSIS; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; LUTEINIZING HORMONE; MALE; MARKOV CHAINS; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; TESTOSTERONE;

EID: 84876151073     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.13.13     Document Type: Article

References (23)

1. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9(Suppl. 1), S3-S8 (2007
2. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J. Natl Compr. Canc. Netw. 8(2), 211-223 (2010
3. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 75(3), 642-647 (2010
4. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59(4), 572-583 (2011
5. Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 57(5), 836-842 (2010
6. Fisher D, Brereton NJ, Nielsen SK, Tate E. A cost utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in Scotland. Presented at: ISPOR 14th Annual European Congress. Madrid, Spain, 5-8 November 2011
7. Lu L, Peters J, Roome C, Stein K. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 109(8), 1183-1192 (2012
8. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group Phase III study in patients with prostate cancer. BJU Int. 102(11), 1531-1538 (2008
9. Crawford ED, Tombal B, Miller K et al. A Phase III extension trial with a 1-arm crossover from leuprolide to degarelix: Comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 186(3), 889-897 (2011
10. Gittelman M, Brown TM, Holm-Larsen T, Persson B. Comparison of the impact of degarelix and leuprolide on the healthrelated quality of life of patients with prostate cancer: Results of a 12-month Phase III clinical trial. Uro Today Int. J. 4(6), Abstract 81 (2011
11. Heidenreich A, Bellmunt J, Bolla M et al.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: Dcreening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59(1), 61-71 (2011
12. Arias E. United States life tables, 2007. Natl Vital Stat. Rep. 59(9), 1-60 (2011
13. Roberts MS, Sonnenberg FA. Decision modeling techniques. In: Decision Making in Health Care: Theory, Psychology, and Applications. Chapman GB, Sooenberg FA (Eds). Cambridge University Press, Cambridge, UK (2000
14. Yabroff KR, Lamont EB, Mariotto A et al. Cost of care for elderly cancer patients in the United States. J. Natl Cancer Inst. 100(9), 630-641 (2008
15. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl Cancer Inst. 92(21), 1731-1739 (2000
16. Fryback DG, Dunham NC, Palta M et al. US norms for six generic health-related quality-of-life indexes from the National Comparison of degarelix with leuprolide in hormonal therapy Expert Rev. Pharmacoecon Med. Care 45(12), 1162-1170 (2007
17. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine: Report of the Panel on Cost- effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996
18. Grosse SD. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8(2), 165-178 (2008
19. Ferguson JK, Oesterling JE. Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol. Clin. North Am. 21(4), 677-685 (1994
20. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. Urol. Clin. North Am. 21(4), 677-685 (1994
21. Montie JE. Follow-up after radical prostatectomy or radiation therapy for prostate cancer. Urol. Clin. North Am. 21(4), 673-676 (1994
22. Scher HI. Management of prostate cancer after prostatectomy: Treating the patient, not the PSA. JAMA 281(17), 1642-1645 (1999
23. Konski A, Watkins-Bruner D; RTOG (Radiation Therapy Oncology Group) Outcomes Model. The RTOG Outcomes Model: Economic end points and measures. Expert Opin. Pharmacother. 5(3), 513-519 (2004